Vor Biopharma (VOR) Revenue & Revenue Breakdown
Vor Biopharma Revenue Highlights
Vor Biopharma Revenue by Period
Vor Biopharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Vor Biopharma generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Vor Biopharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $12.23M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | - |
Vor Biopharma generated - in revenue during Q1 2024, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Vor Biopharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals | $270.26M | $112.21M |
| ACLX | Arcellx | $110.32M | $27.38M |
| KYMR | Kymera Therapeutics | $78.59M | $3.74M |
| NRIX | Nurix Therapeutics | $76.99M | $12.59M |
| FHTX | Foghorn Therapeutics | $34.16M | $6.89M |
| BOLT | Bolt Biotherapeutics | $7.88M | $1.27M |
| AUTL | Autolus Therapeutics | $1.70M | - |
| STTK | Shattuck Labs | $1.66M | $1.61M |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| DSGN | Design Therapeutics | - | - |
| CGEM | Cullinan Oncology | - | - |
| GRCL | Gracell Bio | - | - |
| NUVL | Nuvalent | - | - |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| TALS | Tourmaline Bio | - | - |
| ACET | Adicet Bio | - | - |
| ERAS | Erasca | - | - |
| VTYX | Ventyx Biosciences | - | - |
| VOR | Vor Biopharma | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |
VOR Revenue FAQ
What is Vor Biopharma’s yearly revenue?
Vor Biopharma's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. VOR's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Vor Biopharma’s quarterly revenue?
Vor Biopharma's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $12.23M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022). VOR's quarterly revenue for Q3 2023 was $0, a 100.00% increase from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022).
What is Vor Biopharma’s revenue growth rate?
Vor Biopharma's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.